SI-BONE, Inc. Launches SI Joint Women's Health Initiative at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego, March 14 - 17

Educational Program Brings Together Patients, Health Care Providers and Business Thought Leaders to Raise Awareness of SI Joint Disorders

SAN JOSE, Calif., March 8, 2017 /PRNewswire/ -- SI-BONE, Inc., an innovative medical device company that pioneered the use of the iFuse Implant System® ("iFuse"), a triangular shaped minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, announced the launch of the SI Joint Women's Health Initiative at the American Academy of Orthopaedic Surgeons (AAOS) 2017 annual meeting in San Diego.  The inaugural meeting will take place on Thursday, March 16th, with a reception from 5:00pm to 6:30pm followed by a dinner program from 7:00 to 8:30pm.

The SI Joint Women's Health Initiative is a broad based educational program supported by orthopedic spine surgeons, neuro spine surgeons and associated healthcare providers who are passionate about women's health and focused on raising awareness about SI joint disorders in women.  The kick-off meeting at AAOS is open to all surgeons, physician assistants and nurse practititioners who diagnose and treat patients with lower back pain symptoms and who are interested in learning more about how the SI joint can be a contributing factor for women with chronic lower back pain.

Multiple studies have shown that 15 to 30% of all lower back pain can be attributed to the SI joint and of those suffering with SI joint disorders, roughly two-thirds are women.  Anatomic and physiologic gender differences result in women being more susceptible to SI joint injury particularly during pregnancy and delivery.  Approximately half of all women have pelvic pain during pregnancy and one-fourth experience pain after pregnancy.1  Symptoms often disappear after childbirth however, in postpartum women, 20% have significant pain three years following childbirth.2

The opening meeting of the SI Joint Women's Health Initiative at AAOS will be hosted by Alexis Waguespack, MD, from Spine Care Medical Group in New Orleans and honored as a Becker's Spine Review Top 10 Female Orthopedic Surgeon.  The reception will also feature guest speaker Karen Licitra, former Vice President of Johnson & Johnson Global Medical Solutions Group and Fortune 50 Most Powerful Women in Business and Jesi Payne, mother of three and bi-lateral iFuse Implant System® patient recently featured in Cosmopolitan Magazine.

Space is limited but there are seats still available and registration is required.  To register to attend or learn more about this important women's health event, please email Reena Mishra, Director of Product Marketing, at rmishra@si-bone.com. 

About SI-BONE, Inc.
SI-BONE, Inc. (San Jose, California) is a leading innovative medical device company dedicated to the development, manufacture and commercialization of minimally invasive surgical devices for the treatment of patients with low back symptoms related to certain sacroiliac (SI) joint disorders.  SI-BONE, Inc. first received 510(k) clearance to market its iFuse Implant System ("iFuse") from the Food and Drug Administration (FDA) in November 2008. The CE mark for European commercialization was obtained in November 2010. 

About the iFuse Implant System
The iFuse Implant System provides a minimally invasive surgical solution to fuse the SI joint using patented triangular titanium implants that create an interference fit within the ilium and sacrum.  The triangular implant shape, combined with the press fit insertion, is designed to provide immediate fixation by minimizing rotational motion.  The implants have a porous surface that provide an ideal environment for bone ongrowth and ingrowth*, facilitating long-term fusion of the joint.  The iFuse Implant System is the only commercially available SI joint fusion system in the United States with published prospective clinical evidence that demonstrates safety, effectiveness and economic benefits, including three large multicenter studies, two of which are randomized controlled trials.  Currently, there are 50 peer-reviewed publications supporting positive clinical outcomes, safety, biomechanics, and the economic benefits of iFuse (www.si-bone.com/results).  The iFuse Implant is the only SI joint fusion device with an FDA clearance recognizing demonstrated improvements in pain, patient function and quality of life following treatment.

The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.  This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months.  Clinical studies have demonstrated that treatment with the iFuse Implant improved pain, patient function, and quality of life.  There are potential risks associated with the iFuse Implant System.  It may not be appropriate for all patients and all patients may not benefit.  For information about the risks, visit: www.si-bone.com/risks

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2017 SI-BONE, Inc. All Rights Reserved. 9849.030817

1. Wu WH, et al. Pregnancy-related pelvic girdle pain (PPP), I: Terminology, clinical presentation, and prevalence. Eur Spine J. 2004;13:575–89. Epub 2004 Aug 27.
2. Norén L, et al. Lumbar back and posterior pelvic pain during pregnancy: a 3-year follow-up. Eur Spine J. 2002;11;267-71.

One or more of the individuals named herein may be a past or present SI-BONE employee, paid consultant, investor, clinical trial investigator, or grant recipient. Research described herein may have been supported in whole or in part by SI-BONE.

*Data on file: TR 300401-A and 300359-A

SOURCE SI-BONE, Inc.